Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIOMET trial in adolescents and young adult women with PCOS
2024-518527-29-00Phase 2Completed
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Nov 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, randomised trial of spironolactone + pioglitazone + metformin, spironolactone, pioglitazone and metformin in polycystic ovary syndrome (PCOS) (4 arms), sponsored by Fundació Sant Joan de Déu. Primary endpoints: On-treatment ovulation rate and Post-treatment ovulation rate. Started Nov 2024; status: completed.
02
Drugs
spironolactone + pioglitazone + metforminspironolactonepioglitazonemetformin
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2024-518527-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518527-29-00.